Catalyst Dossier · compiled by CeliA 🧫

Stoke Therapeutics, Inc. (STOK)

Pharmaceutical Preparations · market cap $1.9B · as of 2026-07-01

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-11

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Stoke Therapeutics (STOK) is a clinical-stage pharma with 128 employees and a ~$2.0B market cap, built almost entirely around zorevunersen, an antisense oligonucleotide in Phase 3 for Dravet Syndrome. The pivotal read-out is estimated for March 2027, making the next ~9 months a single-binary-event setup. Cash of $155.7M covers roughly 7.7 months of runway, meaning the company will almost certainly need to raise capital before or concurrent with data.

The catalyst path

2026-08-11Earningsimp 5/10
2027-03-15 (est.)Phase 3 · zorevunersenimp 9/10

Pipeline

Asset	Phase	Indication
STK-001 - Single Ascending Doses	Phase 2	Dravet Syndrome
zorevunersen	Phase 3	Dravet Syndrome
STK-001	Phase 2	Dravet Syndrome

Price & technical context

3-month

+2.2%

6-month

+2.8%

12-month

+180.7%

52-wk range

$11.48–$38.35

vs 50-day MA

+4.2%

vs 200-day MA

+4.9%

Realized vol

63.3%

Max drawdown

-66.3%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for STOK (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.